Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Haleon PLC ( (GB:HLN) ) has shared an update.
Haleon PLC has announced a regulatory notification concerning transactions by Persons Discharging Managerial Responsibilities (PDMRs) within the company. This disclosure includes the acquisition of partnership shares and matching shares awarded under the company’s Share Reward Plan by Adrian Morris, the General Counsel, and Tamara Rogers, the Chief Marketing Officer. The transactions were conducted at the London Stock Exchange, highlighting Haleon’s commitment to transparency and regulatory compliance.
More about Haleon PLC
Haleon PLC is a prominent player in the consumer health industry, dedicated to improving everyday health with a human touch. The company’s diverse product range includes Oral Health, Pain Relief, Respiratory Health, Digestive Health, as well as Vitamins, Minerals, and Supplements. Its portfolio features well-established brands such as Advil, Sensodyne, and Centrum, which are recognized for their scientific reliability and innovative approach.
YTD Price Performance: 18.47%
Average Trading Volume: 20,345,052
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £33.88B
Learn more about HLN stock on TipRanks’ Stock Analysis page.
